Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

A new study by researchers at Intermountain Health in Salt Lake City finds that 40 percent of newly diagnosed heart failure patients also have atrial fibrillation – a combination of cardiac disorders ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Valuable data can successfully be collected with the noninvasive wearable, which is worn on the sternum, report investigators ...

According to research conducted by Johns Hopkins University, a form of heart failure known as heart failure with a preserved ejection fraction or HFpEF is responsible for more than half of all heart ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the flagship journal of the American College of Cardiology, ...

Beta-blocker treatment can lead to a modest increase in depressive symptoms among patients who have myocardial infarction with preserved left ventricular ejection fraction (LVEF).

The stock options are subject to the terms and conditions of the Tenaya Therapeutics Inc. 2024 Inducement Equity Incentive Plan and related forms of agreements, and were granted as an inducement ...

Preservation of normal LV ejection fraction (LVEF). Reduction or stabilization of cardiac biomarkers (median cTnI and ...

Approximately €70 Million in Upfront and Near-term Payments to Cytokinetics Up to €490 Million in Commercial Milestone Payments, with<br / ...

The American Heart Association and the Arizona Cardinals gathered representatives from 12 local schools for cardiopulmonary ...